PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding the disease • Pathogenesis • Signs and symptoms • Diagnosis • Management • Epidemiology PART 06: Pipeline analysis • Lebrikizumab • Tipelukast • Tralokinumab • FG-3019 • Simtuzumab • BMS-986020 • AF-219 • SAR156597 • BG00011 • PRM-151 • PBI-4050 PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by ROA • Oral • Parenteral PART 09: Market segmentation by drug class • Systemic corticosteroids • Immunosuppressants • Tyrosine kinase inhibitors • Anti-fibrotic agents PART 10: Geographical segmentation • Global idiopathic pulmonary fibrosis market by geographical segmentation 2015-2020 • Idiopathic pulmonary fibrosis market in Americas • Idiopathic pulmonary fibrosis market in EMEA • Idiopathic pulmonary fibrosis market in APAC PART 11: Market drivers • Special regulatory designations for pipeline candidates • Growth in patient population • Unmet medical needs PART 12: Impact of drivers PART 13: Market challenges • Unknown disease etiology • Lack of proper diagnosis • Increased use of off-label and alternative therapies PART 14: Impact of drivers and challenges PART 15: Market trends • Patient assistance programs • Increase in M&A • Rise in public awareness PART 16: Vendor landscape • Competitive scenario • Market share analysis 2015 • Baxter International • Boehringer Ingelheim • F Hoffmann-La Roche • Prometheus Laboratories • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Common symptoms of idiopathic pulmonary fibrosis Exhibit 03: Other signs and symptoms of idiopathic pulmonary fibrosis Exhibit 04: Treatment options for idiopathic pulmonary fibrosis Exhibit 05: Drugs used in the treatment of idiopathic pulmonary fibrosis Exhibit 06: Global idiopathic pulmonary fibrosis market: Pipeline portfolio Exhibit 07: Global idiopathic pulmonary fibrosis market 2015-2020 ($ billions) Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global idiopathic pulmonary fibrosis drugs market by ROA Exhibit 10: Global idiopathic pulmonary fibrosis drugs market segment by drug class Exhibit 11: Global idiopathic pulmonary fibrosis market segmentation by geography 2015 Exhibit 12: Idiopathic pulmonary fibrosis market revenue by geography 2015-2020 ($ millions) Exhibit 13: Idiopathic pulmonary fibrosis market in Americas 2015-2020 ($ millions) Exhibit 14: Idiopathic pulmonary fibrosis market in EMEA 2015-2020 ($ millions) Exhibit 15: Idiopathic pulmonary fibrosis market in APAC 2015-2020 ($ millions) Exhibit 16: Key drivers Exhibit 17: Impact of drivers Exhibit 18: Key challenges Exhibit 19: Impact of drivers and challenges Exhibit 20: Key trends Exhibit 21: Baxter International: Business segmentation by revenue 2014 Exhibit 22: Baxter International: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 23: Baxter International: Geographical segmentation by revenue 2014 Exhibit 24: Baxter International: Key takeaways Exhibit 25: Boehringer Ingelheim: Business segmentation by revenue 2014 Exhibit 26: Boehringer Ingelheim: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 27: Boehringer Ingelheim: Geographical segmentation by revenue 2014 Exhibit 28: Boehringer Ingelheim: Key takeaways Exhibit 29: F Hoffmann-La Roche: Business segmentation 2014 by revenue Exhibit 30: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions) Exhibit 31: F Hoffmann-La Roche: Geographical segmentation by revenue 2014 Exhibit 32: F Hoffmann-La Roche: YoY growth and revenue generated from CellCept 2011-2014 ($ millions) Exhibit 33: F.Hoffmann-La Roche: Key takeaways Exhibit 34: Prometheus Laboratories: Product categories Exhibit 35: Prometheus Laboratories: Key takeaways

Baxter International, Boehringer Ingelheim, F.Hoffmann-La Roche, Prometheus Laboratories, Afferent Pharmaceuticals, Amgen, Biogen, Bristol-Myers Squibb, Cipla, FibroGen, Gilead Sciences, GlaxoSmithKline, GNI Group, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune (subsidiary of AstraZeneca), Novartis, Pfizer, Promedior, ProMetic Life Sciences, Sanofi, Shionogi, Zai Lab.